UroToday

Trends in the Diagnoses of Subtype Histologies in Bladder Cancer - Expert Commentary

Wallace BK, Su ZT, Flynn JP, Garman TS, Weitzner A, Rezaee ME, et al. National trends in diagnoses of subtype histologies in bladder cancer: A population-based study based on the SEER database. Urol ...
UroToday

WSAUA 2025: Long-Term Outcomes of Primary Chemoablation of New-Onset or Recurrent Low Grade Upper Tract Urothelial Carcinoma with UGN-101, a Mitomycin …

Patients with low-grade upper tract urothelial carcinoma who achieved a complete response after receiving treatment with ...
UroToday

WSAUA 2025: Impact of Neoadjuvant Systemic Therapy on Tumor and Tumor Thrombus Regression in Renal Cell Carcinoma with Venous Involvement: A Retrospective Analysis

The 2025 Western Section AUA annual meeting featured a kidney cancer session and a presentation by Jaxson Jeffery discussing the impact of neoadjuvant systemic therapy on tumor and tumor thrombus ...
UroToday

EAU 2021: Apalutamide for Metastatic Castration-Sensitive Prostate Cancer: Outcomes in High-Volume and Low-Volume Disease From the TITAN Final Analysis

(UroToday.com) At the metastatic prostate cancer session at the European Association of Urology 2021 Virtual Meeting, Dr. Simon Chowdhury presented results of outcomes in high and low-volume disease ...
UroToday

ESMO 2024: Prostate Cancer Efficacy Results from a Randomized Phase 3 Evaluation of Transdermal Estradiol Versus LHRH Agonists for Androgen Suppression in M0 Prostate Cancer

ESMO 2024, Prostate Cancer, transdermal estradiol, LHRH agonists, Transdermal Estradiol Versus LHRH Agonists, Androgen Suppression in M0 Prostate Cancer, STAMPEDE trial.
UroToday

ASCO 2021: VISION Study Results – Phase III Study of Lutetium-177-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer

(UroToday.com) In this presentation, Dr. Michael Morris presented the results of the phase 3 VISION trial evaluating the radiopharmaceutical lutetium-PSMA (Lu-PSMA) in patients with metastatic ...
UroToday

The Latest Testicular Cancer Research

Laparoscopic Retroperitoneal Lymph Node Dissection after Chemotherapy for Nonseminomatous Testicular Germ-Cell Tumor at a Single Center - Beyond the Abstract ...
UroToday

ASCO GU 2022: The TRAP Trial: Targeting Resistant Prostate Cancer, with or without DNA Repair Defects, Using the Combination of Ceralasertib and Olaparib

(UroToday.com) The 2022 GU ASCO Annual meeting included a prostate cancer session highlighting work from Dr. Zachery R. Reichert and colleagues presenting results of the TRAP trial, targeting ...
UroToday

ESMO 2021: Final Overall Survival Analysis From ARCHES: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Enzalutamide + ADT in Men With mHSPC

(UroToday.com) In the Proffered Paper Session of the European Society for Medical Oncology (ESMO) Annual Congress focusing on prostate cancer, Dr. Andrew Armstrong presented the final overall survival ...
UroToday

Bladder Cancer

New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations November 13, 2025 Epidemiology, treatment patterns and effectiveness of adherence to Bacillus ...
UroToday

ASCO GU 2022: PROpel: Phase III Trial of Olaparib and Abiraterone Versus Placebo and Abiraterone as First-Line Therapy for Patients with Metastatic Castration-Resistant ...

(UroToday.com) In this presentation, Dr. Fred Saad presented results of the PROpel study. PROpel is a randomized phase III trial of abiraterone plus olaparib versus abiraterone plus placebo as ...
UroToday

Managing BCG-Unresponsive NMIBC: Treatment Strategies, Progression, and Emerging Therapies

Sam Chang and Bernard Bochner discuss a novel antibody treatment targeting the CD40 receptor for non-muscle invasive bladder cancer resistant to BCG therapy. Dr. Bochner presents findings from a phase ...